Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis
Clinical and Translational Oncology · 02.11.2026
DOI: 10.1007/s12094-026-04599-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 02.11.2026. Verfasst von Parsa Radfar und 6 weiteren Autor:innen. Beteiligte Einrichtung: John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, 301 University Blvd, TX, 77555. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Purpose
Pretreatment antibiotic exposure has been associated with inferior outcomes during immune checkpoint inhibitor (ICI) therapy, but whether this reflects an ICI specific effect or underlying clinical vulnerability remains uncertain.
Methods
Adults with non-small cell lung cancer (NSCLC) treated with ICIs from 2015 through 2024 were identified in the TriNetX Research Network. Recent antibiotic exposure was defined as systemic antibiotic use during days 30 to 1 before ICI initiation. Propensity score matching balanced clinical and treatment-related covariates. Primary outcomes were all cause mortality at 90 and 365 days. Sensitivity analyses included landmarking, remote exposure, infection stratification, and a non-ICI comparator.
Results
Among 68,723 patients, 19,080 had recent antibiotic exposure; 17,955 per group remained after matching. Mortality was higher with antibiotic exposure at 90 days (17.7% vs 13.7%; HR 1.34, 95% CI 1.27 to 1.41; P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- John Sealy School of Medicine, University of Texas Medical Branch, Galveston, USA, 301 University Blvd, TX, 77555.
- Division of Cardiovascular and Thoracic Surgery, University of Texas Medical Branch, Galveston, USA, TX. aigritsi@utmb.edu.
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Texas Medical Branch, Galveston, USA, TX.
- Division of Medical Oncology and Hematology, University of Texas Medical Branch, Galveston, TX, USA.
- Division of Cardiovascular and Thoracic Surgery, University of Texas Medical Branch, Galveston, USA, TX.
Zitieren
APA
Radfar, P., Gritsiuta, A. I., Marinelli, M., Yazditabar, J., Nishi, S. P., Willis, M., & Petrov, R. V. (2026). Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04599-9
Vancouver
Radfar P, Gritsiuta AI, Marinelli M, Yazditabar J, Nishi SP, Willis M, et al. Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04599-9
BibTeX
@article{Radfar2026,
author = {Radfar, Parsa and Gritsiuta, Andrei I and Marinelli, Margaux and Yazditabar, Joshua and Nishi, Shawn P and Willis, Maurice and Petrov, Roman V},
title = {Pretreatment antibiotic exposure and mortality following immune checkpoint inhibitor therapy in non-small cell lung cancer: an infection-stratified propensity-matched analysis},
journal = {Clinical and Translational Oncology},
year = {2026},
doi = {10.1007/s12094-026-04599-9}
}
EUVIMED